Evidence-based asthma management in children — what’s new?

Peter P Van Asperen, Craig M Mellis, Peter D Sly and Colin F Robertson
Med J Aust 2011; 194 (8): . || doi: 10.5694/j.1326-5377.2011.tb03025.x
Published online: 18 April 2011

The Thoracic Society of Australia and New Zealand has updated its guidelines on corticosteroid use in childhood asthma

The understanding of childhood asthma has increased substantially since the publication of the Thoracic Society of Australia and New Zealand (TSANZ) position statement The role of corticosteroids in the management of childhood asthma in 2002.1 In particular, recognition of the need for separate asthma management guidelines for children aged 5 years or younger has increased,2 and considerably more clinical research evidence on the role of asthma medications in children has become available. The 2010 revision of the TSANZ position statement provides updated recommendations on the roles of inhaled corticosteroids, oral corticosteroids, leukotriene receptor antagonists and combination medications (inhaled corticosteroids plus long-acting β-agonists) in childhood asthma management based on recently published evidence.3 The role of leukotriene receptor antagonists in the management of childhood asthma has also been addressed in detail in a recent National Asthma Council Australia information paper.4

  • 1 Sydney Medical School, University of Sydney, Sydney, NSW.
  • 2 Department of Respiratory Medicine, The Children’s Hospital at Westmead, Sydney Children’s Hospitals Network, Sydney, NSW.
  • 3 Queensland Children’s Medical Research Institute, Brisbane, QLD.
  • 4 Department of Respiratory Medicine, Royal Children’s Hospital, Brisbane, QLD.
  • 5 Department of Respiratory Medicine, Royal Children’s Hospital, Melbourne, VIC.
  • 6 Department of Paediatrics, University of Melbourne, Melbourne, VIC.
  • 7 Murdoch Childrens Research Institute, Melbourne, VIC.


Competing interests:

Peter Van Asperen, Craig Mellis and Colin Robertson are members of the MSD (Australia) Paediatric Respiratory Physician Advisory Board and have received speaker fees from MSD (Australia) for presentations on management of asthma and wheeze in children. They are also members the GlaxoSmithKline Paediatric Respiratory Taskforce, which was convened to ensure appropriate prescribing of Seretide in children. Craig Mellis has also received payment for reviewing topics and chapters of UpToDate (an electronic textbook).


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.